Several otoprotective agents have been studied and are in various stages of research and clinical trials:
Amifostine: Originally developed as a radioprotective agent, amifostine has shown promise in protecting against cisplatin-induced ototoxicity. Sodium Thiosulfate: This agent has been effective in reducing cisplatin-induced hearing loss in pediatric patients without compromising the drug's efficacy against cancer. N-acetylcysteine (NAC): As an antioxidant, NAC has been studied for its potential to protect against oxidative stress-induced damage in the inner ear. D-methionine: This amino acid derivative has shown protective effects in animal models and is under investigation in human trials.
